Newcastle Clinical Trials Unit

Staff Profile

Dr Emma Clark

Trial Manager

Background

Personal Summary

From basic science research, I have moved my research interest focus to the next stage to facilitate gaining evidence to change clinical practice as quickly as possible. I work with mainly NIHR portfolio clinical trial studies.

Qualifications

 PGCert 2015 Clinical Research, Newcastle University, UK
 PhD 2006 Molecular Cancer Biology, Newcastle University, UK
 BSc 1999 (Hons) Biochemistry, University of Sussex, UK

Areas of expertise

Clinical Trial Management (NIHR funded studies)
Translational Clinical Trial Management (assay development, clinical and biological validation and clinical utility)
Biomarker Discovery (companion/predictive in terms of treatment/disease outcomes, personalised medicine)
Urology based research specialising in molecular biology of hormone escape in Cancer

Previous Positions

2006-2020 Research Associate - Urological Cancer, Northern Institute for Cancer Research, Newcastle University, UK
2002- 2005 BBSRC (GSK Case) PhD Student - Institute for Cell & Molecular Biosciences, Newcastle University, UK
2001-2002 Research Assistant - Dept. of Fetal Medicine, Birmingham Women's Hospital, UK
1999-2001 Graduate Pharmaceutical Scientific Researcher - Roche, Welwyn Garden City, UK
1997-1998 Industrial Studentship Placement - Home Office Forensic Science Service, Birmingham, UK

Membership/Committees

UK CRC registered Clinical Trials Units Network
UK TMN Trial Managers Network
UK NCRI Clinical Trials Pathology Advisory Group (CT-PAG)
Faculty of Medical Science Newcastle University Ethics committee member

Research

Current Studies

1) NIHR HTA CONFORM-OH (Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: A Randomised Controlled Trial). Pragmatic, open label, randomised, prospective, superiority, multi-arm, multi-stage clinical trial with a 10-month internal pilot, phase IV. ISRCTN: 87213295.
2) NIHR HTA PREMISE (Prostate Resection versus Minimally Invasive Surgery Evaluation Trial). Multi-arm, multi-centre, non-inferiority randomised controlled trial, with six-month internal pilot. ness of three minimally invasive treatments (MITS) compared to transurethral resection of prostate (TURP) for treatment of bladder outlet obstruction (BOO) due to enlarged prostate ISRCTN: 50571778 

Previous Studies

1) NIHR HTA NAIROS surgery ENT intervention trial (multi-site, pragmatic, randomised phase III trial: ISRCTN: 16168569).
2) Lead applicant for NIHR RfPB VARIANT advanced prostate cancer treatment biomarker trial (multi-site, biomarker guided, randomised feasibility funder reference: PB-PG-0816-20043).
3) Lead on translational arm (PHOTO-T) for HTA NIHR bladder cancer surgery intervention PHOTO trial (multi-site, pragmatic, randomised controlled phase III trial: ISRCTN 84013636). 
4) Commercial (Sanofi) advanced prostate cancer chemotherapy treatment response trial (single-site, pragmatic, observational trial CSP 102842).

Previous Funding 

Clinical Trials:
NIHR RfPB feasibility study (The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Trial (The VARIANT trial) - A multicentre feasibility study of biomarker-guided personalised treatment in advanced prostate cancer - £276,230.00) awarded to Dr. E. L. Clark/ Mr R Heer (June 2018 - Sept 2020).
Basic Science:
PCUK PhD post (Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate resistant prostate cancer - £100.3K) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Sept 2013-Sept 2016) 
JGWP technical support post (Assessing the role of RNA helicase p68 (Ddx5) in the deregulation of microRNAs and progression of Prostate Cancer - £52K) awarded to Dr. E. L. Clark/Prof. C. N. Robson (May 2012-May 2013)
Prostate Action project grant (Assessing RNA helicase p68 (Ddx5) as a biomarker in the deregulation of microRNAs in Prostate Cancer - £99,987) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Jan 2012-Oct 2013)
PCRF project grant (Pharmacological perturbation of p68 - an important androgen receptor transcriptional co-regulator in prostate cancer - £99,941) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Jan 2008- Dec 2011)
Industrial Relevance

 

Teaching

Postgraduate Teaching

Past students:

Alex Lloyd MRes (2017 - 2018)

Emma Smith MRes (2016 - 2017)

Andrew Evans MRes (2015 - 2016)

James Grey PhD (2014 - 2016)

Victoria Shuttleworth UG (2011 - 2012)

Jake Clayton MRes (2010 - 2011)

Christiana Hadjimichael MRes (2007-2008)



Publications